Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Definitions and classification
3. Fibrinoid necrosis of the artery
4. Chapel hill nomenclature
5. PAN: 1990 ACR criteria
6. PAN and MPA
7. Vasculitides and nephrons
8. Capilaritis in lungs
9. Epidemiology
10. Microscopic polyangiitis
11. Wegener's granulomatosis (1)
12. Churg-Strauss syndrome
13. Seine-St-Denis survey
14. Prevalence
15. Incidence of vasculitides in three European areas
16. Why vasculitis is more frequently observed today?
17. Time trends: Wegnere's granulomatosis
18. Age specific incidence of vasculitis
19. Pathogenesis
20. ANCA in systemic vasculitis
21. Role of PR3 in pathogenesis
22. ANCA induce glomerulonephritis in mice
23. Stage A - resting PR3
24. Stage B - stimulation by primary antigen
25. Stage C - adhesion molecules expression
26. Stage D - binding
27. Stage E - activation
28. Stage F - destruction
29. Injury
30. Pathogenesis - other mechanisms
31. Treatment
32. EUVAS and FVSG
33. Treatment of systemic vasculitis (1)
34. Assessment
35. Assessment in necrotizing vasculitis
36. Five factor score
37. Prognostic scores in PAN, MPA and CSS
38. BVAS (different versions)
39. Survival curve: according to CYC dose
40. Survival curve: according to CYC and FFS
41. Survival curve: according to CYC and BVAS
42. Optimization of conventional treatments
43. Oral cyclophosphamide
44. Recommendations for pulse cyclophosphamide
45. Pulse cyclophosphamide
46. Oral vs. pulse CYC in Wegener's
47. Wegener's granulomatosis: 50 patients (1)
48. Wegener's granulomatosis: 50 patients (2)
49. ANCA+ vasculitides
50. CYCLOPS - study design
51. CYCLOPS - epidemiology
52. Outcomes
53. Disease free survival
54. Deaths
55. Poor prognosis and steroids treatment
56. Treatment: PAN, MPA and CSS (1)
57. Treatment of CSS: FFS = 0
58. Treatment of patients with poor prognosis
59. Treatment: PAN, MPA and CSS (2)
60. PAN/MPA patients treated with 6/12 CY pulse CS
61. Treatment of systemic vasculitis (2)
62. CYCAZAREM protocol
63. CYCAZAREM protocol: results (1)
64. CYCAZAREM protocol: results (2)
65. CYCAZAREM protocol: results (3)
66. NORAM protocol
67. NORAM protocol: results
68. The WEGENT study
69. The desighn of WEGENT study
70. WEGENT study: no. of patients
71. WEGENT study: statistics
72. Relapse-free survival curves in the WEGENT study
73. Event-free survival curves in the WEGENT study
74. Wegener's vs. MPA in the WEGENT study
75. Plasma exchanges - MEPEX protocol
76. Plasma exchanges (MEPEX study): survival
77. Plasma exchanges (MEPEX study): renal recovery
78. New drugs and new treatments
79. Mycophenolate in vasculitis
80. IMPROVE strudy
81. Treatment of vasculitides with etanercept
82. Biologics in systemic vasculitis
83. Monoclonal anti-CD20 (rituximab)
84. Rituximab in Wegener's
85. RAVE study
86. How to treat relapses and refractory patients?
87. Relapses of systemic vasculitis (1)
88. Relapses in Wegener's granulomatosis
89. Wegener's prognostic factors (1)
90. Wegener's prognostic factors (2)
91. IGANCA protocol (1)
92. IGANCA protocol (2)
93. Methotrexate in Wegener's (1)
94. Methotrexate in Wegener's (2)
95. Other treatment for relapses
96. Anti-TNF
97. Infliximab in necrotizing vasculitides
98. Treatment of vasculitides with infliximab (1)
99. Treatment of vasculitides with infliximab (2)
100. Relapses of systemic vasculitis (2)
101. Prevention of relapses
102. Specific treatments for specific problems
103. Treatment of systemic vasculitis (3)
104. PAN and CSS after 65 (1)
105. PAN and CSS after 65 (2)
106. Wegner's granulomatosis (2)
107. Example from a patient (1)
108. Example from a patient (2)
109. Conclusion (1)
110. Conclusion (2)
111. Learn more about vasculitides

Topics Covered

• Definitions and classification
• PAN- versus ANCA-associated vasculitides
• Epidemiology
• Pathogenesis
• Treatment
• Optimization of conventional treatments
• Assessment
• New drugs and strategies
• Relapses
• Specific treatments for specific problems

Links

Series:

• Autoimmunity

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on October 25, 2018

Financial Disclosures

• Prof. Loic Guillevin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.